BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 22277275)

  • 1. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
    Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
    J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization.
    Murthy R; Kamat P; Nunez R; Madoff DC; Gupta S; Salem R; Yao JC
    J Vasc Interv Radiol; 2008 Jan; 19(1):145-51. PubMed ID: 18192482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.
    Kis B; Shah J; Choi J; El-Haddad G; Sweeney J; Biebel B; Mellon E; Frakes JM; Hoffe SE; Fishman MN; Shridhar R
    J Vasc Interv Radiol; 2017 Feb; 28(2):254-259. PubMed ID: 27955832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival.
    Bangash AK; Atassi B; Kaklamani V; Rhee TK; Yu M; Lewandowski RJ; Sato KT; Ryu RK; Gates VL; Newman S; Mandal R; Gradishar W; Omary RA; Salem R
    J Vasc Interv Radiol; 2007 May; 18(5):621-8. PubMed ID: 17494843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization in patients with hepatic metastases from breast cancer.
    Jakobs TF; Hoffmann RT; Fischer T; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Reiser MF; Helmberger TK
    J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    IƱarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
    Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R
    Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first report of radioembolization for hepatic metastases from ocular melanoma.
    Kennedy AS; Nutting C; Jakobs T; Cianni R; Notarianni E; Ofer A; Beny A; Dezarn WA
    Cancer Invest; 2009 Jul; 27(6):682-90. PubMed ID: 19219675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
    Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
    Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary?
    McCann JW; Larkin AM; Martino LJ; Eschelman DJ; Gonsalves CF; Brown DB
    J Vasc Interv Radiol; 2012 May; 23(5):661-7. PubMed ID: 22440592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
    Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
    Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study.
    Lewandowski RJ; Riaz A; Ryu RK; Mulcahy MF; Sato KT; Kulik LM; Gates VL; Baker T; Omary R; Salem R
    J Vasc Interv Radiol; 2009 Dec; 20(12):1557-63. PubMed ID: 19854068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.
    Piana PM; Gonsalves CF; Sato T; Anne PR; McCann JW; Bar Ad V; Eschelman DJ; Parker L; Doyle LA; Brown DB
    J Vasc Interv Radiol; 2011 Oct; 22(10):1373-9. PubMed ID: 21764600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.